The genomics and informatics approaches have enabled us to identify genes that meet the conventional definition for ER target genes (for example, responsive to E2, sensitive to ICI, and insensitive to CHX), are conserved in ER+ breast cancer cell lines and tumor samples, and encode putative ER-binding sites in the promoter regions. The gene discussed is ESR1; the disease is neoplasm.